Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
CHICAGO, May 3, 2017 /PRNewswire/ -- Chicago based Rheoxtech LLC has appointed David W.J. Smith as its first President. David has 30 years' experience in founding, developing and providing successful exits for medical device businesses and their investors. He originally started his career in the UK, before moving to the US and immersing himself in medical device startup companies in the San Francisco Bay Area. His most recent notable success was as the founding CEO of Tenaxis Medical Inc, a surgical sealant business. He coordinated the development, regulatory approvals and product commercialization for the company. He assisted in raising $22M for the company over 4 different funding series. Tenaxis Medical was acquired by The Medicines Company in 2014 for a payment of up to $178M. Beyond this, David has deep and broad experience in the fields of interventional cardiology, cardiac and vascular surgery, general surgery and ophthalmology.
Rheoxtech was founded by cardiac surgeon Neil J. Thomas MD and serial entrepreneur Gintaras Vaisnys. It is building on the pioneering work of Dr Thomas, a longtime proponent of controlling cardiac oxygen re-exposure as part of the protection of the heart during surgery, particularly for patients that are hemodynamically unstable and those in cardiogenic shock.
Mr. Vaisnys commented, "We are delighted to attract someone of David's caliber to this critical role. He has exactly the right blend of project management, fund raising and business development experience we were seeking to drive outstanding shareholder returns."
Rheoxtech LLC is a closely held private company, committed to the development of devices for protected reperfusion in percutaneous coronary intervention (PCI) and cardiac surgery.
yes Nagy and this FBDU rns confirms that we are expecting sales in Korea.
i like this share - theres no drilling risk, no spud, no topsoil movement, the cost base here is generally very low. Imaging Biometrics acquistion was a masterstroke.
Added more today. Liked the new guys forward statement. Interesting fdbk rns, we deal with the same distributor in Korea.
IB also completed the code modifications required to port its software to a PC-based DICOM viewer. The viewer is analogous to the Apple (Mac) based platform, OsiriX, which was the initial host platform for IB software "plug-ins". This is a significant opportunity as the vast majority of health care systems and clinics are predominately PC-based. Thus, it is anticipated that sites who are interested in accessing IB's advanced imaging solutions will find an easier path for adoption with a PC-based offering.
The IB Clinic suite of products is currently being evaluated by a number of leading institutions for incorporation into their radiology practices and we have seen a marked increase in the number of demonstrations requested for our suite of software products from opinion leading institutions. We would expect some of these inquiries to be converted into sales revenue during H2 2018 and H1 2019.
The DICOM thing is a huge game changer for IB.
I am surprised more people are not commenting on the Revenue growth of IB. half year faster than the whole of last year
guys. just leave it now. if he posts again on feedback then fine your welcome here to rinse. ill keep an eye on feedback also.
draft ,, Both yourself and Smudge are highly respected and successful investors
I think your resident ceo here has a touch of the Jose Mourinho ( litwl man syndrome )
There's 250k available to buy on line - that seems like a reasonable amount.
"I have worked in the medical device business for 30 years, and as an entrepreneur in the field for the last 15 years, seeking out opportunities to improve patient healthcare and create outstanding value for shareholders. Often this work has been focused on producing a better, more efficient tool for use in the operating room. The improvements in health care delivery have been important, but relatively small, yet the businesses have been financially successful.
When I was approached by Flying Brands to become their COO, and the CEO of their operating businesses, what immediately struck me was the opportunity to be the architect in the way that healthcare is delivered. This is an opportunity for a leap in healthcare, not the creeping change I have previously successfully delivered. A healthcare revolution, not the evolution I have previously managed.
Imagine a world where expensive and invasive medical treatments are only used on patients that truly need it. Currently, resource consuming and painful biopsies are sought to confirm the presence or absence of disease in the face of ambiguous results from medical imaging. In an average hospital, hundreds of scans are taken daily, searching for disease. Imagine a software that is capable of detecting diseased patients and differentiating them from healthy patients, allowing healthcare practitioners to focus their care on the patients that need it the most. Imagine a software that improves its diagnostic capability over time, becoming more intelligent with each successful diagnosis and providing this knowledge and 'Artificial Intelligence' to those responsible for our healthcare.
I believe that Flying Brands through its operating businesses, has the capability to develop the software able to deliver such a revolution ".
definitely a buyer here working in the background... full ask to buy and not many available.
If he keeps posting about how bad he thinks TexRAD is or starts up his negativity towards the Feedback board of directors again then I reserve the right to tell everyone here what I have on him. I don't particularly want to as I am a nice bloke by nature but enough is enough. An apology from him wouldn't go amiss either but I suspect I've got sod all chance of that happening.
Okay, I hope no further comments, comments like that dont help anyone. I will keep eye on FDBK bb also
Today & on both d
Botak and Elartu, what was the last date TB popped up and ****ged off feedback? and on avdfn or on here?
Can you give me the user ID please?
I have been a buyer here recently and today Interim report really does reinforce my reasons for buying.
Sub placing price (still!).
Funded for over 12 months.
FDA approval imminent.
Revenues commencing.
Tiny MCap.
Tiny free float.
Director holds 30% of the company.
New COO is incredibly passionate and bullish about this technology.
Risk v reward here now very compelling reaffirmed by being funded for 12months and being at the sharp end of huge company making newsflow.
Will continue to add on weakness.
Whilst I think its very poor form for for peep,s posting negative poop on other bb when they dont hold the stock,For an X bod member and a highly influential director at that to pop up on a public forum posting continues negative **** purely out of spite and harboring a childish vendetta is not only unethical its very worrying if I were a holding shares in a company he was CEO of ,Mr TB was held in high esteem by a lot of PI,s including myself and I know a lot of successful Pi,s on here like draft and Smudge who believe in the TB story,But Hey guy,s trolling around public forums like a kid who had his sweets nicked is not rational behavior, And ac using the bod of Feedback of : suckering in pi,s : is the kettle calling black,How many AIM CEO,s do we know that are honest ?? Certainly not Mr TB,, So to accuse other directors of cheating pi,s when thats the name of the game on AIM is ludicrous and just demonstrates how desperate and out of touch with reality the ceo of fbdu has become
Dangerous times for you guy,s ,Whilst TexRAD or Cadran might not be world beating right now there a dam sight more advanced that that piece of junk stonechecker
We have tried but he persists on trashing Feedback and TexRAD on a regular basis. As we are unable to stop this demented old man from continuing his tirade against Feedback I felt that just for once I would bring a flavour of what he puts us shareholders through back to his own company's board. If he stops then so will I.
Elartu - I am not aware that what you are saying has ever happened? Mayeb you take that up directly with ceo?
FBDU did explain on interview they were working closely with FDA and decided to revise the application to compare against a device more familiar to the FDA. A lot of info regarding FDA timeline is explained in todays rns
Feedback PLC (FDBK) TexRAD� ordered by Samsung Medical Centre in Seoul
we haev ISG Korea also and Stonechecker uses Texrad.
Agree that’s a great rns. Although we are still Awaiting the fda approval, at least there is an update and it strongly seems that we are on the right track. Akers bio were expecting fda approval and I think they were asked to review their application . Not too sure if they even got it ? Ah well let’s hope by end of year we get the approval
Well on track. Revenue was £126,000 - thats 50% ahead of where Imaging Biometrics usually is. IB was £165,000 for 12 months revenue last time, now in just 6 months its done £126,000! Thats £252,000 for 12 months and we know IB is predicted to go up to ££500,000 a year in 2019 ($250,000 per quarter recurring as in prospectus)
Looks like you are busy posting useful info on fbdu. Just wish the company could give us more updates - when is that fda approval coming. That unlocks so much potential.
Draft
Milwaukee Certainly is a small place, isn’t that where Kathleen Schmainda works (Medical College of Wisconsin, Milwaukee (MCW))....